EyePoint, Inc. (EYPT) Presents at Citigroup’s Biopharma Back to School Summit 2026 Transcript
EyePoint, Inc. (EYPT) Citigroup’s Biopharma Back to School Summit 2026 September 9, 2026 8:00 AM EDT
Company Participants
Jay Duker – President, CEO & Director
Ramiro Ribeiro – Chief Medical Officer
George Elston – Executive VP & CFO
Conference Call Participants
Yigal Nochomovitz – Citigroup Inc., Research Division
Presentation
Yigal Nochomovitz
Citigroup Inc., Research Division
All right. So welcome, everyone, to Day 1 of Citi’s Back-to-School Biopharma Conference here in New York City. Great to be back in New York. I’m Yigal Nochomovitz, one of the biotech analysts here at Citi.
So our first session, it’s my great pleasure to welcome the management of EyePoint Inc. We have Jay Duker, President and CEO; George Elston, EVP and CFO; and Ramiro Ribeiro, the CMO of the company. So welcome all of you. Thank you very, very much.
Jay Duker
President, CEO & Director
Thanks for having us.
Question-and-Answer Session
Yigal Nochomovitz
Citigroup Inc., Research Division
Of course. So obviously, a lot has happened. You’ve had some Phase III data. You have another important — very important Phase III result coming up soon in the fall. So Jay, maybe just to level set, if you could just introduce the company, introduce the goals of your lead program. And then I know we’re going to have an important discussion about the LUGANO results and then what to expect, of course, for LUCIA in a few weeks.
Jay Duker
President, CEO & Director
Sure. Thanks for the introduction, and thanks for the invitation. So at EyePoint, we are a company that specializes in drug delivery to the back of the eye. Our lead product is called DURAVYU. It is the vorolanib intravitreal insert. Vorolanib is a small molecule tyrosine kinase inhibitor, which has activity against all the VEGF receptors, PDGF, and JAK1, giving it an anti-inflammatory component.
